Ekso Bionics Appoints Corinna E. Lathan, Ph.D. to its Board of Directors
December 28 2021 - 4:05PM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, today announced the appointment of Corinna E.
Lathan, Ph.D. to its Board of Directors, effective immediately.
“We are pleased to expand our Board with the
addition of Dr. Lathan, who brings a successful track record of
robotics, engineering and business experience,” said Jack Peurach,
President and Chief Executive Officer of Ekso Bionics. “Dr. Lathan
is a recognized leader in the biomedical industry. As a visionary
in the field of robotics, combined with her board experience, we
look forward to her unique perspectives as we grow our business and
advance our mission.”
Dr. Lathan has over twenty years of experience
as a leader and technology innovator with deep expertise in
human-technology interfaces for robotics and mobile technology
platforms. She co-founded AnthroTronix, a biomedical engineering
research and development company that creates diverse products in
robotics, digital health, wearable technology, and augmented
reality, and has led it as Board Chair and Chief Executive Officer
for over 20 years. She currently serves on the board of PTC, Inc.,
a global technology provider of Internet of Things and Augmented
Reality platforms, and is a member of its Audit and Cybersecurity
Committees. In addition, Dr. Lathan previously served as Associate
Professor of Biomedical Engineering at The Catholic University of
America and as Adjunct Professor of Aerospace Engineering at the
University of Maryland, College Park.
“I am delighted to join the Ekso Bionics Board
and support the company in bringing pioneering solutions across
medical and industrial applications,” said Dr. Lathan. “Ekso’s
innovative platform has positioned the company for long-term
growth, and I am excited to contribute to their future
successes.”
About Ekso
Bionics® Ekso Bionics® is a leading
developer of exoskeleton solutions that amplify human potential by
supporting or enhancing strength, endurance, and mobility across
medical and industrial applications. Founded in 2005, the Company
continues to build upon its industry-leading expertise to design
some of the most cutting-edge, innovative wearable robots available
on the market. Ekso Bionics is the only exoskeleton company to
offer technologies that range from helping those with paralysis to
stand up and walk, to enhancing human capabilities on job sites
across the globe. Ekso Bionics is headquartered in the San
Francisco Bay Area and is listed on the Nasdaq Capital Market under
the symbol “EKSO.” For more information, visit: www.eksobionics.com
or follow @EksoBionics on Twitter.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding the plans, objectives and expectations of
management with respect to the Company’s commercial strategy and
future revenues or other financial results and the assumptions
underlying or relating to the foregoing. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance
the Company’s technology, the significant length of time and
resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of the Company’s sales and
marketing efforts or of partners to market the Company’s products
effectively, adverse results in future clinical studies of the
Company's medical device products, the failure of the Company to
obtain or maintain patent protection for the Company's technology,
the failure of the Company to obtain or maintain regulatory
approval to market the Company's medical devices, lack of product
diversification, existing or increased competition, disruptions in
the Company’s supply chain due to the outbreak of the COVID-19
virus, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit the
Company’s website at www.eksobionics.com or refer to the Company’s
Twitter page at @EksoBionics. The Company does not undertake to
update these forward-looking statements.
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024